Inhibition of USP1 reverses the chemotherapy resistance through destabilization of MAX in the relapsed/refractory B-cell lymphoma

The patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL) have poor prognosis, and a novel and effective therapeutic strategy for these patients is urgently needed. Although ubiquitin-specific protease 1 (USP1) plays a key role in cancer, the carcinogenic effect of USP1 in B-ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xi-Ya, Wu, Ji-Chuan, Liu, Ping, Li, Zi-Juan, Wang, Yong, Chen, Bing-Yi, Hu, Cheng-Long, Fei, Ming-Yue, Yu, Peng-Cheng, Jiang, Yi-Lun, Xu, Chun-Hui, Chang, Bin-He, Chen, Xin-Chi, Zong, Li-Juan, Zhang, Jia-Ying, Fang, Ying, Sun, Xiao-Jian, Xue, Kai, Wang, Li, Chen, Shu-Bei, Jiang, Shi-Yu, Gui, Ai-ling, Yang, Ling, Gu, Juan J., Yu, Bao-Hua, Zhang, Qun-ling, Wang, Lan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883169/
https://www.ncbi.nlm.nih.gov/pubmed/36352191
http://dx.doi.org/10.1038/s41375-022-01747-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883169/
https://www.ncbi.nlm.nih.gov/pubmed/36352191
http://dx.doi.org/10.1038/s41375-022-01747-2

Ejemplares similares